SYMPROIC.com
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Osaka Japan. All Rights, Raleigh, North ...Website
www.symproic.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About SYMPROIC.com
Symproic ® (naldemedine) is indicated for the treatment of OIC in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Symproic ® was made available to patients in the US in October 2017. Please see Important Safety Information, including Warnings & Precautions, and Adverse Reactions below .Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SYMPROIC.com your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on SYMPROIC.com recently announced quarterly report
Product Launch: Get notified when SYMPROIC.com launches new products
Congratulate Masked Content for being promoted to Masked Content at SYMPROIC.com
Funding: Get notified immidiatlly once SYMPROIC.com has new funding data
Check if SYMPROIC.com has recently received funding, and reach out quickly before it becomes old news!
SYMPROIC.com, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if SYMPROIC.com had a recent Job posting/layoffs
Check out if SYMPROIC.com is spiking on competitors!
Recommended Actions
Find VP level buyers at SYMPROIC.com
Find 2 more new buyers
Compare Similar Companies to SYMPROIC.com
Compare insights from companies similar to SYMPROIC.com, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
SYMPROIC.com
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
SYMPROIC.com is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SYMPROIC.com is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SYMPROIC.com.
SYMPROIC.com Tech Stack
A closer look at the technologies used by SYMPROIC.com
See more technologies
SYMPROIC.com News & Media
BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million LivesShionogi Announces Licensing of Symproic® (naldemedine) to BioDelivery Sciences International Inc.
OSAKA, Japan & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc. (hereafter "Shionogi") announced today that BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, has licensed full rights to commercialize Symproic® (naldemedine) tablets 0.2 mg in the United States. The transfer of rights is effective immediately. Symproic is an oral tablet which functions as a peripherallyBioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Long-term revenue potential of over $75 million for NME with IP protection through 2031
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SYMPROIC.com
Sign Up For FreeTo access detailed company insights
Symproic ® (naldemedine) is indicated for the treatment of OIC in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Symproic ® was made available to patients in the US in October 2017. Please see Important Sa... Read More
